Results 171 to 180 of about 3,830,389 (286)

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients Than in Most Nonhemophiliacs With Factor VIII Autoantibodies [PDF]

, 1997
Richard Prescott, Hiroaki Nakai, Evgueni L. Saenko, I. Scharrer, Inga Marie Nilsson, John Eric Humphries, Deborah Hurst, Gordon L. Bray, Dorothea Scandella, the Recombinate and Kogenate Study Groups   +9 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [PDF]

, 2002
Roland Buhl, G. Hanf, M. Solèr, George Bensch, Jeremy D. Wolfe, F Everhard, Kate Champain, H. Fox, J. Thirlwell   +8 more
openalex   +1 more source

The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose [PDF]

, 2021
Fabio Fiorino, Anna Sicuranza, Annalisa Ciabattini, Adele Santoni, G Pastore, Martina Simoncelli, Jacopo Polvere, Sara Galimberti, Stefano Auddino, Claudia Baratè, Francesca Montagnani, Vincenzo Sammartano, Monica Bocchia, Donata Medaglini   +13 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. [PDF]

, 1997
Deng‐Pan Wu, Jing Yang, William M. Pardridge   +2 more
openalex   +1 more source

The Dual Role of the TRAIL-DR5 Signaling Axis in Cardiovascular Disease: From Molecular Mechanisms to Targeted Therapies

Biologics: Targets & Therapy
Run Cao,* Wenqing Qi,* Xinyu Huang, Yalun Zheng, Rudan Zheng, Yuanfang Ma, Hailong Zhang Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, Henan University, Kaifeng, Henan, People’s Republic of China ...
Cao R, Qi W, Huang X, Zheng Y, Zheng R, Ma Y, Zhang H   +6 more
doaj  

Correlating Stimulated Emission Depletion Microscopy With Fluorescence Lifetime Imaging Microscopy to Study the TIE2 Protein on Kidney Glomerular Podocytes. [PDF]

J Histochem Cytochem
Dénes IA, Okkelman IA, Keersmaecker H, Cornillie P, Dmitriev RI, De Spiegelaere W.   +5 more
europepmc   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source